GWENT FORMULARY DECISIONS
|
|
- Arleen O’Neal’
- 6 years ago
- Views:
Transcription
1 Dear Gwent Prescriber At its last two meetings (9 th September and 21 st October 2010) the Gwent Partnership Medicines & Therapeutics Committee (GPMTC) made the following decisions in relation to the Aneurin Bevan Health Board (ABHB) Joint Formulary: GWENT FORMULARY DECISIONS Pivmecillinam (Selexid ) for the treatment of UTIs. ADDED the MTC agreed there were no requirements for prescribing guidelines and that pivmecillinam could be initiated by both specialists and non specialists. However, in accordance with the application, the MTC agreed pivmecillinam should be reserved for use on the recommendation of a medical microbiologist only. Empirical use is not recommended. Etonogestrel (Nexplanon ) for contraception ADDED noting that Implanon is due to be discontinued, that the cost of Nexplanon is set to remain the same as Implanon, and that The Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit state they are bioequivalent ( Barium sulphate has been added to make Nexplanon radio opaque. The CEU also state there are no differences in their safety profile and that the UK Medical Eligibility Criteria for Contraceptive Use of progestogen only implants will also apply to Nexplanon. +subdermal+use/ Dronedarone ( Multaq ) for the treatment of non permanent AF ADDED in accordance with the recommendations in NICE TA197 (Atrial fibrillation Dronedarone is recommended as an option for the treatment of non permanent AF only in people: 1. whose AF is not controlled by 1 st line therapy (usually including beta blockers), that is, as a 2 nd line treatment option, and 2. who have at least one of the following cardiovascular risk factors: hypertension requiring drugs of at least 2 different classes diabetes mellitus previous transient ischaemic attack, stroke or systemic embolism left atrial diameter of 50 mm left ventricular ejection fraction < 40% (noting that the SPC does NOT recommend dronedarone for people with left ventricular ejection fraction < 35% because of limited experience of using it in this group) or age 70 years or older, and 3. who do not have unstable NYHA class III or IV heart failure. The MTC agreed that it be designated a specialist only initiated medicine with continued prescribing by non specialists in Primary Care requiring no Shared Care arrangements (i.e. Amber WITHOUT Shared Care in the Gwent Traffic Light system). Compliance with NICE TAG197 through an audit of initiations of dronedarone has been agreed with ABHB Cardiology. Page 1 of 5
2 Fentanyl intranasal spray ( Instanyl ) for breakthrough pain ADDED in accordance with minister endorsed AWMSG s recommendation (0710) as an option in adults already receiving maintenance opioid therapy for chronic cancer pain. Consistent with the decision on Abstral the MTC agreed that Instanyl be designated a specialist only 1 initiated medicine with continued prescribing by non specialists in Primary Care requiring no Shared Care arrangements (i.e. Amber WITHOUT Shared Care in the Gwent Traffic Light system). Gwent Palliative Care have agreed to draw up a position statement of the use of these 2 forms of Immediate Release fentanyl for Gwent. This is awaited. mcg+dose+nasal+spray/ Sildenafil 20mg ( Revatio ) for pulmonary arterial hypertension ADDED BUT minister endorsed AWMSG recommendation (1010) has restricted the use of Revatio to a physician experienced in the treatment of PAH in association with a National Commissioning Group designated expert centre. This concurs with all non erectile dysfunction use of sildenafil being previously designated Red in Gwent by the GPMTC. Pramipexole prolonged release (Mirapexin Prolonged Release) for Parkinson s disease ADDED in accordance with minister endorsed AWMSG recommendation (0810). Consistent with the MTC s previous decision on Immediate Release (IR) pramipexole, it was agreed to designate the Prolonged Release (PR) form as Amber with Shared Care. The existing Gwent Shared Care Protocol for IR pramipexole will be revised to cover the use of the PR pramipexole. Formulary News The ABHB Joint Formulary on the GPMTC website (in Word format at and as linked from CWS Main Menu page) now incorporates the Supplementary List of formulary additions and is currently up to date. Until the web based version of the ABHB Joint Formulary (Inform) is in place this Word version will be updated on a continual basis. OTHER PRESCRIBING NEWS Mixtard 30 Discontinuation Further to the interim guidance in the summer enewsletter ( ed 29/07/2010) joint advice from the ABHB Diabetology Directorate & the GPMTC has now been issued and is available at: df NOTE this has been previously circulated to all Gwent GP Practices (on 19 th August) 1 Appropriate only for initiation by specialists in palliative care and oncology/haematology (within a consultant led team) or by accredited GPs with a special interest in palliative care. Page 2 of 5
3 Rosiglitazone containing medicines Avandia and Avandamet Advice from the ABHB Diabetology Directorate has recently been issued on the options for managing patients on rosiglitazone. This is available at: NOTE this has been previously circulated to all Gwent GP Practices (on 28 th October). Decline to Accept Prescribing Responsibility Form Prescribers are reminded they can use this form if they have concerns about accepting requests from Secondary/Tertiary Care specialist to prescribe unlicensed, off label or non formulary medicines. The form (at: now includes a revised Fax number and should be the version used from now on. ABHB Policy on use of Off label and Unlicensed Medicines A number of recommendations made by GPMTC have been incorporated into this ABHB Policy The Policy has now been endorsed by ABHB Clinical Standards & Policy Group and it is available at: Guidelines for the Treatment of Under Nutrition in the Community In previous discussions on the best way to guide the prescribing of nutritional supplements (both sip and tube feeds) the GPMTC agreed that as tube feeds were initiated predominately in Secondary Care, on the advice of dietitians, that any dietary products formulary would be most effectively applied to Secondary Care only; whereas guidance on the use of sip feeds would be more helpful for Primary Care. The MTC has now endorsed local Guidelines for the Treatment of Under Nutrition in the Community Including Advice on Oral Nutritional Supplement Prescribing and are available at: Gluten free Guidance At the end of 2007 the GPMTC agreed to adopt the 2004 Coeliac Society s (now Coeliac UK) guidance on the prescribing gluten free foods. are_professionalsfull_0.pdf This guidance states: Gluten free foods available on prescription (Table 2 P.8) only includes Bread/rolls Plain biscuits Crackers and crispbreads Flour / flour type mixes Pasta Pizza bases Other gluten free foods, such as cereals, cakes and ready meals, are not prescribable but are available from retail outlets (p.9) ADVICE TO GWENT PRESCRIBERS IS THAT LUXURY ITEMS SUCH AS CHOCOLATE BISCUITS SHOULD NOT BE PRESCRIBED BUT SHOULD BE PURCHASED FROM SUPERMARKETS OR HEALTH FOOD STORES. NOTE: Plain sweet biscuits and cake mixes may be prescribed. Page 3 of 5
4 New Shared Care Protocols The following Gwent protocols have recently been developed or updated: 1. DALTEPARIN (Fragmin ) NEW for extended treatment and prophylaxis of VTE in patients with solid tumours. Note this has been previously circulated (with background information) to all Gwent GP Practices on 26 th August. 2. APOMORPHINE injection (APO go Pen) NEW for the treatment of disabling motor fluctuations in Parkinson s disease. Note this Protocol does NOT currently extend to the pre filled syringes (APO go PFS) used as a continuous subcutaneous infusion by minipump and / or syringe driver. It does cover the ready loaded disposable pens (APO go Pen) for giving self administered intermittent injections: 3. SULFASALAZINE in RA UPDATED in line with the 2008 British Society for Rheumatology / British Health Professionals in Rheumatology guideline for DMARD therapy. The monitoring requirements are now 3 monthly for 1 year and if the results are stable after first year, 6 monthly tests will suffice thereafter. NOTE ALL GWENT SHARED CARE PROTOCOLS CAN BE FOUND AT: Ketamine specialist prescribing only but local guidance for healthcare professionals is now available Gwent Palliative Care have recently developed the following resources for ketamine: 1. Specialist guidelines for using ketamine 2. Ketamine Administration 3. Ketamine Information for community pharmacists 4. Ketamine Patient Information Leaflet They have also developed a Patient Information Leaflet on Strong Pain Killers and Driving All 5 documents can be found at: NOTE these do not affect the recent classification of ketamine (all formulations) as a Red drug in Gwent. Neuropathic Pain Following discussion on the local implementation of NICE Clinical Guideline 96 (Neuropathic pain Pharmacological Management) the GPMTC agreed (in consultation with their representative from the ABHB Chronic Pain Team) to issue interim local guidance on the pharmacological management of neuropathic pain in a non specialist setting. The reasons for this variation from CG96 being: the significant additional funding required to implement NICE s first line recommendation for pregabalin, the ongoing review by NICE of the economic modelling that formed the basis for their recommendation on pregabalin, the current economic challenges facing ABHB and there being no statutory requirement on Health Boards to implement NICE Clinical Guidelines (in contrast to NICE Technology Appraisals). The interim local guidance can be accessed at: tersept10.pdf NOTE this guidance has been previously circulated to all Gwent GP practices (on 28 th September). Page 4 of 5
5 Eplerenone revised guidance Further to the item in the March/April 2010 enewsletter about the reclassification of eplerenone from Red to Amber without shared care the Gwent Trust guidelines of 2007 have now been revised to assist the on going prescribing of eplerenone by GPs. The local guidance now incorporates advice on the use of eplerenone as an alternative to spironolactone (when adverse effects limit its continuation) and clearer recommendations on the monitoring of potassium and renal function in Primary Care (in accordance with the recent NICE CG108 Management of chronic heart failure in adults in primary and secondary care The Gwent guidance on the use of eplerenone are available at: l%5daug10.pdf Feedback on any item in this is welcome. Suggested agenda items for the MTC are also welcome! Regards Trevor Batt Pharmacist & Professional Secretary to: Gwent Partnership Medicines & Therapeutics Committee Aneurin Bevan Health Board Based at Torfaen Locality Office, Mamhilad House. NP4 0YP Tel: (DIRECT LINE) Web: Page 5 of 5
FORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber At its last
More informationAneurin Bevan Health Board Medicines & Therapeutics Committee. enewsletter
Aneurin Bevan Health Board Medicines & Therapeutics Committee August 2013 enewsletter Dear Gwent Prescriber At its last two meetings (23 rd May and 11 th July) ABHB s Medicines & Therapeutics Committee
More informationA guide to essential gluten-free foods available from the pharmacy
A guide to essential gluten-free foods available from the pharmacy This information guide has been produced by For further information: This resource has been reviewed by the British Dietetic Association.
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last two meetings (13 th October and 24 th November 2011) ABHB s Medicines & Therapeutics Committee (formerly GPMTC) made the following decisions in relation to the ABHB Joint
More informationSHARED CARE GUIDELINE For
SHARED CARE GUIDELINE For Ketamine in Palliative Care Implementation Date: 26.1.2011 Review Date: 26.1.2013 This guidance has been prepared and approved for use within Gateshead in consultation with Primary
More informationNHS Circular: PCA(M)(2011)4 abcdefghijklmnopqrstu TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH SEVERE DISTRESS. Summary
Directorate for Health and Social Care Integration Primary Care NHS Circular: abcdefghijklmnopqrstu Dear Colleague LIST OF DRUGS SUBJECT TO PRESCRIBING TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH
More informationAlison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG
Alison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG Commissioning is the set of linked activities required to assess the healthcare needs of a population, specify the services
More informationDronedarone for the treatment of non-permanent atrial fibrillation
Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationThis guidance applies to all prescribers, both medical and non-medical.
1 Prescribing Guidance Gluten Free Foods This guidance applies to all prescribers, both medical and non-medical. NHS Dudley has agreed that the prescribing of gluten-free food for patients with a confirmed
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last three meetings (12 th January, 1 st March and 19 th April 2012) ABHB s Medicines & Therapeutics Committee (formerly GPMTC) made the following decisions in relation to
More informationNorth of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
ANEURIN BEVAN UNIVERSITY HEALTH BOARD MEDICINES & THERAPEUTICS COMMITTEE PRESCRIBING enewsletter 28 September 2016 ARCHIVE at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber
More informationHeart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationHeart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationPrescribing Guidelines on Gluten-Free products. Information for GPs
Prescribing Guidelines on Gluten-Free products Information for GPs This guideline should be used in conjunction with NICE clinical guideline 86 Coeliac disease: recognition and assessment of coeliac disease.
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationPRESCRIPTION PAD. The Newsletter of the Cumbria Area Prescribing Committee. February 2012 No. 18. Click here to find more. News from the MHRA
PRESCRIPTION PAD The Newsletter of the Cumbria Area Prescribing Committee February 2012 No. 18 Click here to find more Clinical policy and Formulary news Lothian changes Targeted Medication Use Reviews
More informationFactsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction
North Central London Joint Formulary Committee Factsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction Start date: July 2016 Review date: July 2019 Document
More informationFrimley Health Area Prescribing Committee
Frimley Health Area Prescribing Committee Frimley Health NHS Foundation Trust North East Hampshire and Farnham CCG East Berkshire CCG Surrey Heath CCG Buckinghamshire CCG SHARED CARE Guideline Amber Traffic
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 September 2015 Dear Gwent Prescriber
More informationSpecialist Palliative Care Audit and Guidelines Group (SPAGG)
Specialist Palliative Care Audit and Guidelines Group (SPAGG) Clinical Guideline for the Prescribing and Administration of Furosemide via continuous subcutaneous infusion (CSCI) for Heart Failure Patients
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC)
More informationEFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation
EFFECTIVE SHARED CARE AGREEMENT Dronedarone - For the treatment and management of atrial fibrillation Specialist details Patient identifier Name INTRODUCTION This shared care agreement outlines how the
More informationMMPr001 EMERGENCY CONTRACEPTION PROTOCOL
MMPr001 EMERGENCY CONTRACEPTION PROTOCOL MMPr001 Emergency Contraception - (Sept18-Sept20) Page 1 of 8 Table of Contents MMPr001 EMERGENCY CONTRACEPTION PROTOCOL... 1 Why we need this protocol... 3 What
More informationGLUTEN-FREE FOOD SCHEME. Information Pack
GLUTEN-FREE FOOD SCHEME Information Pack The Tayside Gluten-Free Food Scheme is part of the Scottish Gluten-Free Food Service. There are variations from the Scottish Service and more information can be
More informationPrimary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Rivaroxaban is a non-vitamin K antagonist oral anticoagulant
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee July 2014 PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationReview guidance for patients on long-term amiodarone treatment
Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg
More informationPrescribing Framework for Galantamine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationNorth of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationPalliative Care Impact Survey
September 2018 Contents Introduction...3 Headlines...3 Approach...4 Findings...4 Which guideline are used...4 How and where the guidelines are used...6 Alternative sources of information...7 Use of the
More informationNHS WEST ESSEX CLINICAL COMMISSIONING GROUP
NHS WEST ESSEX CLINICAL COMMISSIONING GROUP Gluten Free Policy Brief Description (max 50 words) Target Audience NHS West Essex CCG Board agreed to restrict the prescription of Gluten Free foods to bread
More informationMedicines Management Group
Title SHARED CARE PROTOCOL for Extended Treatment of symptomatic VTE and prevention of its recurrence in Cancer Patients with Solid and Haematological Tumours Scope: Dalteparin (Fragmin ) may be considered
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More informationEFFECTIVE SHARED CARE AGREEMENT. July Dronedarone (Multaq ) For the treatment and management of atrial fibrillation
Whipps Cross University Hospital NHS Trust EFFECTIVE SHARED CARE AGREEMENT July 2011 Dronedarone (Multaq ) For the treatment and management of atrial fibrillation INTRODUCTION The Whipps Cross University
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic
More informationWALSALL COELIAC DISEASE FLOWCHART
WALSALL COELIAC DISEASE FLOWCHART CLINICAL SUSPICION OF COELIAC DISEASE ( Which can present at any age ) [see Box A or Box B] DO NOT START GLUTEN FREE DIET BEFORE ANY INVESTIGATIONS Test for IgA Tissue
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationQuick reference guide to prescribing adults oral nutritional supplements (ONS)
Quick reference guide to prescribing adults oral nutritional supplements (ONS) Produced by the Medicines Management Team, West Suffolk Clinical Commissioning Group in conjunction with the Dietitians, West
More informationVenous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital
Please Note: This policy is currently under review and is still fit for purpose. Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital This procedural document supersedes
More informationPrimary hypertension in adults
Primary hypertension in adults NICE provided the content for this booklet which is independent of any company or product advertised Hypertension Welcome NICE published an updated guideline on the diagnosis
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Type 2 diabetes: the management of type 2 diabetes (update)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Type 2 diabetes: the management of type 2 diabetes (update) 1.1 Short title Type 2 diabetes (update) 2 Background a) The National
More informationNHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification
NHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) Rationale General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification Aims It is the responsibility of general practitioners
More informationDRUG NAME: EDOXABAN (LIXIANA ) Transfer of Care document Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
More informationHIGH BLOOD PRESSURE. How can we do better?
HIGH BLOOD PRESSURE How can we do better? Review date: February 2018 This publication includes practical guidance from GPs, nurses and pharmacists on how you can improve detection and management of high
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationSCHEDULE 2 THE SERVICES. A. Service Specifications
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy
More informationPatient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015
Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015 Claire James, Senior Pharmacist Clinical Effectiveness, Ninewells Hospital Aims To increase awareness and
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationAppropriate Use of Prescribed Oral Nutritional Supplement (ONS) in the Community
Appropriate Use of Prescribed Oral Nutritional Supplement (ONS) in the Community Aim This guideline sets out a recommended procedure for the identification and treatment of malnutrition to ensure Oral
More informationEAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD MINUTES OF THE MEETING HELD ON WEDNESDAY 15 th NOVEMBER 2017 AT 12.30pm IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationMMPr001 EMERGENCY CONTRACEPTION PROTOCOL
MMPr001 EMERGENCY CONTRACEPTION PROTOCOL Table of Contents MMPr001 EMERGENCY CONTRACEPTION PROTOCOL... 1 Why we need this Protocol... 2 What the Protocol is trying to do... 2 Which stakeholders have been
More informationBuprenorphine used in the treatment of opioid dependence: availability and price
7 th floor Wellington House 133 155 Waterloo Road London SE1 8UG 24 October 2018 Gateway number: L2018-443 Dear Director of Public Health, Buprenorphine used in the treatment of opioid dependence: availability
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationDRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document.
Enclosure No: Agenda item No: Author: Contact: xx/xxxxx/xxxx0918 xx CEPP National Audit: Antipsychotics in Dementia All Wales Therapeutics and Toxicology Centre Tel: 02920 71 6900 awttc@wales.nhs.uk 1.0
More informationSHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD
More informationGuidelines for the Prescribing of Sacubitril / Valsartan
Hull & East Riding Prescribing Committee Guidelines for the Prescribing of Sacubitril / Valsartan 1. BACKGROUND Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor, including both a neprilysin
More informationDianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication
Dianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication Dear Healthcare Professional, In agreement with the European Medicines
More informationGOVERNING BODY REPORT
GOVERNING BODY REPORT DATE OF MEETING: 20th September 2012 TITLE OF REPORT: KEY MESSAGES: NHS West Cheshire Clinical Commissioning Group has identified heart disease as one of its six strategic clinical
More informationPATIENT GROUP DIRECTION FOR THE SUPPLY OF ORLISTAT BY COMMUNITY PHARMACISTS
PATIENT GROUP DIRECTION FOR THE SUPPLY OF ORLISTAT BY COMMUNITY PHARMACISTS November 2009 Orlistat PGD Page 1 of 7 Rationale Patient Group Direction For Supply Of Orlistat By Community Pharmacists To enable
More informationQ&A: Opioid Prescribing for Chronic Non-Malignant Pain
NHS Hastings and Rother Clinical Commissioning Group Chair Dr David Warden Chief Officer Amanda Philpott NHS Eastbourne, Hailsham and Seaford Clinical Commissioning Group Chair Dr Martin Writer Chief Officer
More informationdronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd
dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd 6 August 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationPregabalin Prescribing in Primary Care Audit Results 2012/13
Executive summary Pregabalin Prescribing in Primary Care Audit Results 2012/13 Pregabalin is extensively used across Aneurin Bevan Health Board (ABHB). It is the second highest medicine in terms of primary
More information17/18 Threshold 18/19 Points 18/19. Points NO CHANGE NO CHANGE NO CHANGE
SUMMARY OF CHANGES TO QOF 2018/19 - ENGLAND 18-19 QOF005 KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 17/18 QOF ID 18/19 QOF ID NICE ID Indicator
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationSHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR mg TM ) for precocious puberty
WORKING IN PARTNERSHIP WITH SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR 11.25 mg TM ) for precocious puberty NHS Surrey s Medicines Management Committee classification:
More informationIvabradine for treating chronic heart failure: NICE technology appraisal guidance 267 Information for East Kent GPs revised July 2015
Ivabradine for treating chronic heart failure: NICE technology appraisal guidance 267 Information for East Kent GPs revised July 2015 In November 2012 NICE recommended that: 1.1 Ivabradine is recommended
More informationDegarelix Subcutaneous Injection (Firmagon ) Treatment Guideline
Mid Essex Locality Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline Contents FlowChart 2 Summary... 3 Key points... 3 Introduction... 3 Pharmacology... 3 Product information... 4 Place
More informationGuideline scope Hypertension in adults (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Hypertension in adults (update) This guideline will update the NICE guideline on hypertension in adults (CG127). The guideline will be
More informationSheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)
Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals
More informationAudit support for continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57)
Audit support for continuous subcutaneous insulin (review of technology appraisal guidance 57) Issue date: 2008 Audit support Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationThe contractor establishes and maintains a register of patients with AF
Atrial Fibrillation The contractor establishes and maintains a register of patients with AF G5731 Those patients with AF in whom there is a record of CHADS2 score of 1, the % of patients who are currently
More informationDear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM
Directorate of Chief Medical Officer T: 0131-244 6930 E: john.mitchell4@gov.scot Dear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM Lithium is a
More informationDementia Care Pathway
Document level: West Locality Code: CC41 Issue number: 1 Dementia Care Pathway Lead executive Authors details Type of document Target audience Document purpose Medical Director Dr Anushta Sivananthan Dr
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationNHS QIS National Measurement of Audit Acute Coronary Syndrome
NHS QIS National Measurement of Audit Acute Coronary Syndrome Things have changed based on the experience and feedback from the first cycle of measurement and, for the better we think! The Acute Coronary
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationPRESCRIBING enewsletter
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber At its last
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationCosting Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)
Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical
More informationMONITORING OF MEDICINES APPRAISED BY NICE AND AWMSG SUMMARY
MONITORING OF MEDICINES APPRAISED BY NICE AND AWMSG SUMMARY April 2014 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics and Toxicology
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More information